{
  "id": 1503477,
  "title": "Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China",
  "url": "https://urgent.news/2026/08/17/summit-akesos-ivonescimab-shows-smaller-benefit-with-longer-follow-up",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T14:48:39.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/summit-akesos-ivonescimab-shows-smaller-benefit-with-longer-follow-up-in-china/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Summit Therapeutics and Akeso’s next-generation cancer drug ivonescimab earned an approval in China last week for first-line patients with certain forms of lung cancer. But it came with an updated dataset that may spell trouble ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit",
        "url": "https://urgent.news/2026/08/17/stat-akeso-and-summits-lung-cancer-drug-shows-worsening-tumor",
        "published": "2026-08-17T13:38:15.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}